Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ozone vaginal lavage is a therapeutic intervention that utilizes the potent oxidizing properties of ozone ($O_3$) to treat vaginal infections, specifically nonspecific vaginitis. The treatment involves irrigating the vaginal canal with ozonated water or an ozone-oxygen gas mixture. Ozone acts as a broad-spectrum antimicrobial agent by inducing oxidative stress, which disrupts microbial cell membranes and cell walls, oxidizes proteins, and damages nucleic acids. This mechanism is effective against a wide range of pathogens, including bacteria, fungi, and protozoa. In a Phase 4 multicenter randomized trial in China (ChiCTR-IPR-14005426), ozone vaginal lavage was evaluated for its efficacy in treating nonspecific vaginitis in comparison to Baofukang vaginal suppositories and 3% boric acid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ozone vaginal lavage.